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Point: Steady Progress and Current
Challenges in Clinical Islet Transplantation
T
he ﬁeld of -cell replacement thera-
pies has evolved substantially over
the last decades. The lesson learned
from recent islet transplantation trials in
patients with unstable type 1 diabetes is
that primary goals are the achievement of
stable,normalizedglycemiccontrolinthe
absence of severe hypoglycemic episodes
with improvement of quality of life and
the prevention of progressive, chronic di-
abetes complications. Insulin indepen-
dence, although desirable, should not be
considered the main objective, particu-
larly in light of the sustained positive
effects achieved even with a “marginal”
functional islet mass via restoration of C-
peptidesecretionandreductionofinsulin
requirements.Aspresentlimitationsofis-
let transplantation are progressively over-
come, the clinical application will greatly
expand from the currently limited indica-
tionincontrolledclinicalresearchtrialsto
more widely available cellular therapies
and regenerative medicine solutions that
will eventually be offered as standard
treatment to the majority of patients with
insulin-requiring diabetes.
Vantyghem et al. (1) in the article in
this issue of Diabetes Care evaluated the
predictive value of primary graft function
on long-term clinical outcomes of islet
transplantation alone (ITA). Surrogate
measures have been proposed to monitor
orpredict-cellfunction,buttheyarenot
yet fully validated (2–4). In this report,
the use of the -score in the early post-
transplant period allowed to quantify pri-
mary graft function that, when “optimal,”
was associated with prolonged graft sur-
vival and better metabolic control follow-
ing islet transplantation (1). In agreement
with previous reports using the “Edmon-
ton Protocol” (5–10), this trial resulted in
a signiﬁcant improvement of metabolic
control and long-term graft function
(70%havingmeasurableC-peptideat5
years). Importantly, the investigators also
showed prolonged insulin independence
in 57% of the patients at 5 years, with the
subjects with optimal primary graft func-
tion exhibiting the highest success rates
(70% insulin free and 100% of func-
tioning grafts 4 years) (1). Similar long-
term insulin independence rates have
been reported using novel protocols
basedonlymphodepletingagentsincom-
bination with maintenance immunosup-
pressive regimens minimizing -cell
toxicitythathaveshownsustainedinsulin
independence for 3 years (60%) (9)
and even at 5 years (50%) (11). Collec-
tively, these encouraging results indicate
that ITA may lead to long-term insulin
independence rates that are comparable
to those of pancreas transplant alone
(60% at 5 years) (12) and justify the
need for reassessment of islet trans-
plantation as clinical option for -cell
replacement.
The treatment of choice for patients
with type 1 diabetes consists of exoge-
nous insulin therapy with tailored diet
and physical exercise (13). The impor-
tance of achieving tight glycemic control
has been well established (13,14). Inten-
sive insulin therapy can delay the onset
and reduce the progression of chronic di-
abetes complications (14), but unfortu-
nately, it is associated with a signiﬁcantly
increased number and severity of hypo-
glycemicepisodes(15),particularlyinpa-
tients with long-standing diabetes with
autonomic neuropathy and hypoglyce-
mia unawareness. Indeed, the risk of
experiencing severe hypoglycemia is sig-
niﬁcantly higher under intensive insulin
compared with conventional regimen
(relative risk to experience 1 episode 
3.28) with the same individual being at
higher risk for multiple episodes (22% of
subjectswith5episodesvs.4%,respec-
tively) (15).
Tight glycemic control throughout
the day still remains difﬁcult to attain us-
ing conventional insulin therapy, and the
risk for long-term diabetes complications
has not completely been eliminated. The
use of novel insulin formulations, infu-
sion pumps, and glucose monitoring sys-
tems has substantially improved diabetes
care in recent years, contributing to a sig-
niﬁcant amelioration of quality of life and
to the reduction of chronic complications
andofsideeffectsassociatedwithconven-
tional insulin therapy in patients with
type 1 diabetes. Patients with erratic daily
glycemic excursions, progressive compli-
cations, and hypoglycemia unawareness
are highly susceptible to multiple severe
hypoglycemic events, at times life threat-
ening. Attaining stable metabolic control
in this brittle patient population is of ut-
most importance also in view of the sig-
niﬁcant mortality rate in such subjects,
with apparently normal renal function,
while waiting for a pancreas transplant
(8% at 4 years for pancreas transplant
alone) (16). Thus, medical therapy can-
not attain the desirable therapeutic efﬁ-
cacy in such a selected population of
subjects with type 1 diabetes.
Restoration of -cell function is a
highlydesirablegoalforpatientswithun-
stable type 1 diabetes. -Cells are highly
specializedglucosesensorsabletosecrete
insulin in “real time” to ﬁnely regulate
glucose homeostasis. Indeed, physiologi-
cal metabolic control is attained after
transplantation of pancreatic islets either
as isolated cell clusters or as vascularized
pancreasorgan.Pancreastransplantation,
despite improving glucose control,
chronic complications, and quality of life
and having long graft function and sur-
vival, still has a relatively high periopera-
tive mortality and morbidity and speciﬁc
limitations (12,16). Alternatively, alloge-
neic pancreatic islet transplantation can
be an attractive, minimally invasive, and
saferoptionforthisgroupofpatientswith
unstable type 1 diabetes, by inducing res-
toration of physiological glucose sensing
and insulin delivery. Islet transplantation
occurs by gravity infusion of the heparin-
ized islet product from a closed-bag sys-
tem via microembolization into the
hepatic portal venous system, with the is-
letsentrappinginitsperipheralbranches,
at presinusoid level because of the size
restriction followed by their engraftment
and neovascularization from the hepatic
vasculature, with instant function and
survival. This interventional radiology
procedure is performed by percutaneous
transhepatic catheterization of the main
portal vein branches under ﬂuoroscopic
and ultrasound guidance with local anes-
thesia and conscious sedation and with
close monitoring of portal pressure; it
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from hospital within 48 h, once clinically
stable and without complications (6,17).
Clinical trials in the 1980s and 1990s
were performed in islet-after-kidney
(IAK) and simultaneous islet-kidney
(SIK) transplantation recipients using
corticosteroids and high-dose calcineurin
inhibitors (CNI) or purine antagonists
(8,17). Such protocols were mainly fo-
cused on preserving the kidney graft
function and were associated with diabe-
togenic effects. Clinical outcomes were
overall poor, with many cases of primary
graft nonfunction, low rates of insulin in-
dependence at 12 months (10%), and
limited graft survival. Steady progress in
islet cell processing, novel immunosup-
pressive strategies, and improved patient
management have led to increasing suc-
cess rates of islet transplantation in the
last 30 years (17). In the late 1990s, the
introduction of a steroid-sparing immu-
nosuppressive protocol (the Edmonton
Protocol), consisting of an induction with
anti-CD25 antibody and maintenance
with low-dose CNI and high-dose mam-
malian target of rapamycin (mTOR) in-
hibitors, resulted in sustained (12
months) insulin independence in recipi-
entsofsequentialITA(18).Thisapproach
has proven reproducible (even with some
modiﬁcations)andalsoapplicableforSIK
and IAK transplants (1,6–10,19–21).
Collectively, 650 islet transplants in
325 recipients have been reported since
1999 by the Collaborative Islet Trans-
plant Registry (CITR) (22). Common
achievements of these studies are the im-
proved glucose control and the reduction
of insulin requirements with normaliza-
tion of A1C as well as absence of severe
hypoglycemia, even in patients with par-
tial graft function requiring exogenous
insulin. Islet transplantation is also asso-
ciated with a signiﬁcant improvement of
quality of life that parallels the positive
metabolic effects together with preven-
tion of severe hypoglycemia and restora-
tion of hypoglycemia awareness (8,23).
Insulin independence is usually obtained
when adequate islet numbers, generally
from two or more donor pancreata, are
transplanted (i.e., 10,000–14,000 islet
equivalents per kilogram of recipient’s
body weight). The rate of insulin inde-
pendence at 1 year is 70% (and even
higher in the most experienced centers),
with virtually all patients maintaining a
functioning graft (positive C-peptide),
while under adequate immunosuppres-
sion levels (1,6–10,19–21). Similar re-
sultshavebeenreplicatedinasmallseries
ofsingle-donorITAreceivinglower(mar-
ginal) islet masses (10,000 islet equiva-
lents/kg body wt) while using speciﬁc
lymphodepleting and anti-inﬂammatory
treatmentsatinductionandconversionto
CNI-free maintenance therapy, which in-
cluded the purine synthesis inhibitor my-
cophenolate acid (19,20). As a result of
fewer systemic and -cell negative side
effects, current islet transplantation stud-
ies increasingly include this drug in their
maintenance regimen.
Following islet transplantation, phys-
iological -cell response to secretagogues
is restored to a certain extent, including
improved ﬁrst-phase insulin secretion
upon intravenous stimulation and in-
creasedoverallC-peptidelevelsfollowing
oralchallenge(3).Asmentioned,theneu-
rohormonal and symptomatic responses
to hypoglycemia (e.g., glucagon and epi-
nephrine)arealteredinpatientswithtype
1 diabetes. Although an initial report sug-
gested that intrahepatic islet transplanta-
tion did not restore hypoglycemia
hormonal counterregulation and symp-
tomrecognition(24),morerecentstudies
have shown normalization of the glyce-
mic thresholds for activation of counter-
regulatory hormone and symptom
responses to hypoglycemia, though the
magnitude of such responses remained
impaired (25,26). Glucagon secretion
was also normally suppressed by hyper-
insulinemia in these patients (25). It is
conceivable that all the above-mentioned
phenomena contribute to the observed
posttransplantimprovementofmetabolic
control and to the restoration of hypogly-
cemia awareness after islet transplanta-
tion (27).
Overall, sustained graft survival is
achievedinthemajorityofislettransplant
recipients, with 70% of them retaining
C-peptide levels, normalized A1C, nearly-
absent severe hypoglycemia, and signif-
icantly reduced insulin requirements
(50% from pretransplant dose) at 5
yearsundertheEdmontonProtocol(1,5).
Notably,boththeimprovementinquality
oflifeandtherestorationofhypoglycemia
awareness persist long term (23,27).
However, the rate of insulin indepen-
dence may progressively decline after
transplantation, reaching 10% at 5
years despite maintaining islet graft func-
tion (5).
Recent trials have generally relied on
the use of multiple donor islets to attain
insulin independence. The number and
quality of islets obtained from a donor
pancreas remain quite variable, and
50%ofglandsprocessedwiththeintent
totransplantyieldadequateisletnumbers
(28). The success rate of clinical islet iso-
lations improves (60%) when organ re-
covery is performed by a local team
involved with the transplant program
(28). In an attempt to minimize competi-
tion with vascularized pancreas trans-
plantation, islet transplant programs are
generally offered pancreata that have pre-
viously been offered and turned down for
whole organ transplant as well as glands
obtained from older and obese donors
that are considered less than optimal for
surgical implant (29,30). Notably, this
pancreas allocation scheme does not ac-
count for potential limitations in islet po-
tency and longevity of such organs that
could negatively affect long-term out-
comes of islet transplantation (30). Not-
withstanding the steady increase in organ
donation, pancreas recovery rates remain
unsatisfactoryandmuchlowerthanthose
for other solid organs; e.g., 8,000 mul-
tiorgan donors were available through
the United Network for Organ Sharing
(UNOS) in 2006 (of these, 2,000
pancreata were recovered and only
1,440 used for transplant [http://optn.
transplant.hrsa.gov/data/annualReport.
asp]). In the period 2000–2004, the
poor utilization of potential islet donor
pancreatawasrecordedintheU.S.(30).
In particular, from the overall pool of
pancreata available, 22.3% (“optimal”
glands) were used for whole organ trans-
plant;fromtheremainingpool,48.5%were
considered “suitable islet donors” (11%
“optimal” and 89% “standard”), but only
2.1% of them were actually used for islet
transplantation (30). Therefore, a wide
margin for improvements in organ allo-
cation and utilization exists that include
the use of “optimal” donors and a fair allo-
cation between islets and whole pancreas
transplant programs. In addition, changes
in the current cost structure of pancreas
procurement, which differentiate the pay-
ment based on the transplant suitability of
the islet tissue products (determined after
completion of the manufacturing process)
rather than based on the acceptance of
whole organ transplantation, will help re-
duce the overall economic burden of islet
transplantation (31). In light of the promis-
ingresultsobtainedwithsingle-donormar-
ginal islet mass infusions, when adequate
donor-organ selection and targeted recipi-
entimmuneinterventionsareimplemented
(20), the number of islet transplants could
be substantially improved with the cur-
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satisfy the demand for the relatively con-
tained targeted population that would
greatly beneﬁt from islet transplantation.
Type 1 diabetes–related micro- and
macrovasculopathyarethemaincausesof
chronic end-stage renal disease (ESRD)
requiring dialysis, blindness, and limb
amputations and deformities, with asso-
ciated disabilities, comorbidities, and
death (32). Their impact is 10% of the
totalhealthcareexpenseinwesterncoun-
tries,with100billionsUSDspentevery
year in the U.S. alone and 200 billions
USD worldwide (32). Stabilization or re-
duction of the progression of retinopathy
and neuropathy has been reported after
islet transplantation (33). In IAK recipi-
ents, improvement of cardiovascular and
endothelial function, amelioration of the
atherothrombotic proﬁle, and reduction
of cardiovascular events with better pa-
tient survival rates have been reported
when compared with those of recipients
of renal transplant alone (90% at 7 years
vs. 50%, respectively) (34,35). In addi-
tion, the longevity of the concomitant re-
nal allograft appears to be signiﬁcantly
prolonged following the achievement of a
better metabolic control associated with
islet transplantation (36), although addi-
tional factors (i.e., better organ quality of
the kidney grafts transplanted in recent
years)alsosigniﬁcantlycontributetosuch
improvements (37).
The restoration of C-peptide produc-
tion following islet transplantation may
also contribute to some of the improve-
ment of diabetes complications observed
posttransplant. Indeed, putative mecha-
nisms accounting for the possible beneﬁ-
cialeffectsofC-peptideincludereduction
ofnervedysfunctionandincreaseinmyo-
cardial and renal blood ﬂow as well as in
peripheral vascular districts and tissues
(i.e., skeletal muscle), as suggested from
studies in subjects with long-standing
type 1 diabetes receiving C-peptide infu-
sion. These events, in turn, may contrib-
ute to improve cardiovascular and renal
function, thus possibly reducing the pro-
gression of diabetic angiopathy and re-
lated complications (38).
A current hurdle to more widespread
use of islet transplantation includes the
need for chronic immunosuppression
and its associated untoward side effects.
Therateandtypeofimmunosuppression-
related complications observed in islet
transplant recipients under the Edmon-
ton Protocol are not different from those
reported in solid organ transplants
(mainly opportunistic infections and
drug-related toxicity) and were expected
based on the pharmacological proﬁle of
the current immunosuppressive agents
(39). From data of more than 300 islet
recipients during 10 years of monitor-
ing, procedure- and infusion-related seri-
ous adverse events (e.g., abdominal
bleeding) were extremely rare (6% in
the1styear),withonly2of111casesthat
were not fully resolved. Novel radiologi-
cal techniques, intracatheter tract coagu-
lants, and recipient peritransplant
antithrombotic prophylaxis have signiﬁ-
cantly reduced their occurrence (22). Re-
garding immunosuppression therapies,
despitecommoninfections(e.g.,skinand
urinary tract) and direct drug effect (e.g.,
myelodepressionandgastrointestinaldis-
turbs), only 96 serious adverse events
possibly or deﬁnitely related to immuno-
suppression have been reported, with 82
resolved with no sequelae, 17 with se-
quelae, 6 with persistent condition, and
only one death (viral meningitis). Six
other deaths were reported not directly
related to the islet transplant or its medi-
cations. Neoplasms occurred in 14 islet
recipients,butjust4werepossiblyrelated
to immunosuppression (squamous and
basal cell skin cancers, papillary thyroid
carcinoma, and ovarian cysts) (22).
The negative effects of CNI and
mTOR inhibitors on renal function have
been widely recognized. The potential
negative impact of these drugs on the
progression of diabetic nephropathy in
nonuremicsubjectsneedstobefullyeval-
uated. In the context of islet transplanta-
tion, decline of renal function has been
reported in some studies (7,40,41),
whereas more recent reports have shown
stable renal function and lack of worsen-
ing of diabetic nephropathy in long-term
follow-up (8,42,43) or an initial decline
of renal function that stabilizes without
further worsening in the long term (9).
Notably, strict selection of islet transplant
candidates without previous renal dys-
function (i.e., microalbuminuria and low
estimated glomerular ﬁltration rates) and
timely implementation of nephroprotec-
tive and antihypertensive therapies (i.e.,
inhibitors and/or angiotensin receptor
blockers) may have accounted for the
different clinical outcomes (43). Immu-
nosuppressive protocols void of nephro-
toxicity are highly desirable; indeed,
ongoing clinical trials are showing prom-
ising results in patients undergoing con-
version of either CNI or mTOR inhibitors
tomycophenolateacidmaintenance,with
preservation of both renal and islet func-
tion (8,9,42,43).
Several factors may contribute to the
progressive islet graft dysfunction and
failure observed over time under the Ed-
monton Protocol in addition to the recip-
ient immune response. After an initial
islet mass loss following the intraportal
infusion, as a result of an instant blood-
mediated inﬂammatory reaction and the
deleterious graft hypoxia until engraft-
mentandneovascularization,theintrahe-
patic islets are chronically exposed and
damaged by the high levels of lipids, glu-
cose, and immunosuppressive drugs and
bythelocalinﬂammatorymilieu(44).Di-
rect -cell toxicity and functional impair-
mentconsequenttoexposuretoCNIhave
beenwidelyrecognized.Experimentalev-
idence supports the antiproliferative ef-
fects of mTOR inhibitors and CNI that
may result in impaired islet engraftment
(i.e.,alteredneovascularizationandtissue
remodeling) and reduced -cell self-
renewal (45). Additionally, increased
lipid levels are commonly associated with
immunosuppression (mainly mTOR in-
hibitors) and may result in -cell lipotox-
icitycontributingtolossoffunctionalislet
mass over time (39).
Reproducible, single-donor islet
transplantation is indeed a highly desir-
able goal (20). This is particularly impor-
tant considering the risk of recipient
sensitization to donor alloantigens that is
an expected ﬁnding following solid organ
transplantation (46–48). Islets from
HLA-mismatched, ABO compatible do-
nors are used (with the exception of SIK
recipients) in an attempt to minimize the
riskofrecurrentautoimmunity.Adequate
immunosuppression in islet transplant
recipientsappearstopreventthedevelop-
ment of alloantibodies and to neutralize
their potentially negative impact on graft
survival, even in the presence of low
degree of panel-reactive alloantibodies
pretransplant (47,48). Nevertheless,
posttransplant development of donor-
speciﬁc and non–donor-speciﬁc alloanti-
bodies may be detected after drug dose
reduction (i.e., for medical reasons),
while it invariably occurs when immuno-
suppression is withdrawn (i.e., at islet
graftfailure)(47,48).Althoughthesignif-
icance of this phenomenon and its poten-
tial impact on long-term islet graft
functionorsubsequentallograftshavenot
been established, there is a concern for
potentiallylimitingfuturetherapeuticop-
tions (i.e., subsequent islet, pancreas, or
renal transplantation for ESRD) (47). Se-
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ofdiabeticnephropathywhowillunlikely
develop ESRD as well as attempting
more stringent donor-recipient HLA
matching may contribute to reduce the
risk of allosensitization in islet transplant
recipients (43). It is conceivable that de-
velopment of tailored immunosuppres-
sion weaning protocols after islet graft
loss may be of assistance in reducing the
risk of allosensitization.
Persistence or recurrence of autoim-
munity has been described in islet trans-
plant recipients and has been associated
with lower rates of insulin independence
and shorter graft survival (49). Selective
destruction of -cells within islet allo-
grafts by histopathology analysis, mea-
surable changes of autoantibody levels
(i.e., anti-GAD65 and anti-insulinoma–
associated protein 2), and/or detection of
autoreactive cytotoxic and memory T-
cellsto-cell–speciﬁcepitopeshavebeen
described (50). A close monitoring of im-
mune activation and -cell function
markers during the follow-up may be of
assistanceindetectingearlyisletgraftdis-
tress and possibly guide timely therapeu-
tic interventions (i.e., metabolic support
or immunotherapy) to preserve islet mass
long term (10). This has been shown, for
instance, with the use of exenatide to pre-
serve islet function after detection of graft
dysfunction (51).
Overcomingthecurrentchallengesof
islettransplantationrequiresasequential,
integrated approach aimed at enhancing
the yield and quality of islet cells from a
single-donor pancreas, as well as improv-
ing the survival and function of the trans-
planted islets using safer and more
effective cytoprotective and immuno-
modulatory approaches (17,44). In-
creased islet yields have been obtained
using more efﬁcient pancreas recovery
and preservation as well as islet isolation
and puriﬁcation strategies (17,44). Peri-
transplant interventions aimed at re-
ducing inﬂammation and conferring
cytoprotection to islet cells (i.e., reducing
-cell death) have shown promise in en-
hancing engraftment and improving
long-term outcomes. In the clinical set-
ting, tumor necrosis factor- blockade
enhances islet engraftment and survival
(6,20,22). Similarly, glucagon-like pep-
tide synthetic analogs (i.e., exenatide)
have been introduced to enhance -cell
function and possibly survival after trans-
plantation, with encouraging results in
patients with suboptimal islet masses
both at the time of the islet transplant and
after development of graft dysfunction
(51,52).Translationalexperimentalmod-
els have provided evidence that cytopro-
tective agents (e.g., lisofylline, caspase
and Jun NH2-terminal kinase inhibitors)
notonlyreduceisletcelllossbutalsomay
favor the efﬁcacy of tolerogenic protocols
by modulating local inﬂammation and
immune responses (44,53,54). Although
current immunosuppressive agents pre-
vent rejection via nonspeciﬁc antiprolif-
erativeeffects,thishasacostlytrade-offin
terms of untoward side effects, including
organ and -cell toxicity. Compared with
standard protocols, powerful lymphode-
pleting induction agents (i.e., thymo-
globulin, anti-CD52, anti-CD3, and
anti-CD20 antibodies) are showing
promisingresultsintermsofsafetyproﬁle
and improvement in islet graft function
(19,20,55,56). Immunomodulatory
agents,selectivelytargetingcostimulatory
signals of T-cell activation and/or adhe-
sion molecules, are becoming available
forclinicalapplicationsandmayhaverel-
ativelylowersideeffectsandisletororgan
toxicity (i.e., lack of diabetogenicity and
nephrotoxicity) as well as possibly pro-
mote immune tolerance in speciﬁcally
designed protocols (57). Many of the
above-mentioned agents are currently
under evaluation in the National Insti-
tutes of Heath (NIH)–sponsored Clinical
Islet Transplantation (CIT) Consortium
(www.citisletstudy.org) carrying on
phase II-III randomized ITA and IAK tri-
als both in North America and Europe.
PrimaryobjectivesoftheCITtrialsarethe
conﬁrmation and improvement of the
success rate of islet transplantation and
the standardization of the isolation and
transplant procedures, toward approval
ofislettransplantationasstandardofcare,
reimbursable by health insurance.
Attempting to induce immune toler-
ancetothetransplantedtissuesisanappeal-
ing perspective for islet transplantation
(57). There is an increasing body of experi-
mental data supporting the value of adju-
vant cellular transplants (i.e., bone
marrow–derived cells, mesenchymal cells,
regulatoryT-cells,andtolerogenicdendritic
cells) in order to modulate recipient im-
mune response and to increase the accep-
tance and long-term survival of islet
allografts(58).Notably,recentclinicaltrials
have shown achievement of stable mixed
hematopoietic chimerism and/or opera-
tional tolerance in kidney allograft recipi-
ents using nonmyeloablative conditioning
anddonorhematopoieticstemcellinfusion
(59).
Emerging multidisciplinary ap-
proaches are showing great promise for
-cell replacement therapies in the years
to come. The rapidly evolving ﬁelds of
biomedical engineering and regenerative
medicine will be of assistance in develop-
ingefﬁcientwaystoenhanceisletengraft-
ment and survival. Biocompatible devices
and three-dimensional, functionalized
polymers, in alternative implantation
sites, may also provide an optimal micro-
environment for cell implants and local
delivery of immunomodulatory agents
(60). Cotransplantation of islets with ad-
juvant cells (i.e., mesenchimal and endo-
thelialcells)maycontributetolocaltissue
remodeling, with revascularization and
immune protection. Efﬁcient encapsula-
tion techniques that confer immune iso-
lationwhileprovidingadequateexchange
of nutrients to islet cells may allow long-
term survival after transplantation using
short-termorlowerlevelsofimmunosup-
pression (systemically or locally) (61).
Availability of an unlimited source of
transplantable insulin-producing cells is
highly desirable to overcome the current
inadequate supply of human pancreatic
islet cells for transplantation. Experimen-
tal data support the great potential of
adult and embryonic stem cells to gener-
ate islet cells in vitro, and current efforts
are focused toward improving efﬁciency,
potency, and safety of these cells (62).
Similarly, under appropriate conditions,
expansion and/or differentiation of puta-
tive pancreatic islet cell precursors (ex
vivo or in vivo) as well as the use of cells
that share common embryonic origin
(liver cells) to -cells show great applica-
tive potential. Xenogeneic islets (i.e., por-
cine) remain a viable therapeutic option
for the near future, particularly if com-
bined with immune isolation strategies
and safe immunotherapy (17).
The lesson learned from recent clini-
cal islet transplantation trials in patients
with unstable type 1 diabetes is that pri-
mary goals are as follows: 1) the achieve-
ment of stable, normalized glycemic
control, in 2) the absence of severe hypo-
glycemic episodes with improvement of
quality of life, and 3) the prevention of
progressive, chronic diabetes complica-
tions. Insulin independence, although
desirable, at present should not be con-
sidered the main objective of islet trans-
plantation, particularly in light of the
sustained positive effects achieved with a
“marginal” functional islet mass via the
restoration of C-peptide secretion and
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requirements.
The safety of the patient always re-
mains the priority, and any attempt to
improve metabolic control via islet trans-
plantationshouldbeindeedachievedusing
strategies that minimize any potential
complications. In particular, overall risks
and beneﬁts should be carefully ad-
dressed for each islet transplant candi-
date. Strict inclusion criteria, close
clinical monitoring, and prompt manage-
mentofemergingcomplicationscanmax-
imize the beneﬁts of the transplants while
minimizing side effects. Additionally, re-
cent data have shown the relevance of the
center’s experience in islet cell processing
(7)aswellasthefeasibilityandcontaining
the cost of islet transplantation consortia,
with centralized cell processing facilities
that supply remote transplant centers
(44).
The ﬁeld of -cell replacement thera-
pieshasevolvedsubstantiallyoverthelast
decades, and notwithstanding the limited
patient population size of most studies in
islet transplantation, the steady progress
in this ﬁeld (regarding metabolic control,
diabetes complications, and quality of
life) justiﬁes the renewed optimism for
the potential of cellular therapies in dia-
betes (17). As the current limitations of
islet transplantation are progressively
overcome, the indication for clinical ap-
plicability of these strategies will greatly
expand from the current very limited eli-
gibility criteria in controlled clinical re-
search trials to more widely available
cellular therapies and regenerative medi-
cine solutions that will eventually be of-
fered as treatment to the majority of
patients with insulin-requiring diabetes.
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